MicroRNA Profiling of Follicular Lymphoma Identifies MicroRNAs Related to Cell Proliferation and Tumor Response

Overview

Journal Haematologica

Specialty Hematology

Date 2011 Nov 22

PMID 22102710

Citations 53

Authors

Weixin Wang

Meghan Corrigan-Cummins

Justin Hudson

Irina Maric

Olga Simakova

Sattva S Neelapu

Larry W Kwak

John E Janik

Barry Gause

Elaine S Jaffe

Katherine R Calvo

Affiliations

Soon will be listed here.

Abstract

Background: MicroRNAs can play an important role in tumorigenesis through post-transcriptional regulation of gene expression, and are not well characterized in follicular lymphoma.

Design And Methods: MicroRNA profiles of enriched follicular lymphoma tumor cells from 16 patients were generated by assaying 851 human microRNAs. Tandem gene expression profiles were obtained for predicting microRNA targets.

Results: The expression of 133 microRNAs was significantly different (> 2-fold; P<0.05) between follicular lymphoma and follicular hyperplasia. Forty-four microRNAs in three groups generated a unique follicular lymphoma signature. Of these, ten microRNAs were increased (miR-193a-5p, -193b*, -345, -513b, -574-3p, -584, -663, -1287, -1295, and -1471), 11 microRNAs were decreased (miR-17*, -30a, -33a, -106a*, -141, -202, -205, -222, -301b, -431*, and -570), and 23 microRNAs formed a group that was increased in most cases of follicular lymphoma but showed lower expression in a subset of cases (let-7a, let-7f, miR-7-1*, -9, -9*, -20a, -20b, -30b, -96, -98, -194, -195, -221*, -374a, -374b, -451, -454, -502-3p, -532-3p, -664*, -1274a, -1274b, and -1260). Higher expression of this last group was associated with improved response to chemotherapy. Gene expression analysis revealed increased expression of MAPK1, AKT1, PRKCE, IL4R and DROSHA and decreased expression of CDKN1A/p21, SOCS2, CHEK1, RAD51, KLF4, BLIMP1 and IRF4 in follicular lymphoma. Functional studies indicated that CDKN1A/p21 and SOCS2 expression is directly regulated by miR-20a/-20b and miR-194, respectively.

Conclusions: Follicular lymphoma is characterized by a unique microRNA signature, containing a subset of microRNAs whose expression correlate with response to chemotherapy. miR-20a/b and miR-194 target CDKN1A and SOCS2 in follicular lymphoma, potentially contributing to tumor cell proliferation and survival.

Citing Articles

MicroRNA Expression Profile in Bone Marrow and Lymph Nodes in B-Cell Lymphomas.

Veryaskina Y, Titov S, Kovynev I, Pospelova T, Fyodorova S, Shebunyaeva Y Int J Mol Sci. 2023; 24(20).

PMID: 37894763 PMC: 10606460. DOI: 10.3390/ijms242015082.

EBV and 1q Gains Affect Gene and miRNA Expression in Burkitt Lymphoma.

Akyuz N, Janjetovic S, Ghandili S, Bokemeyer C, Dierlamm J Viruses. 2023; 15(9).

PMID: 37766215 PMC: 10537407. DOI: 10.3390/v15091808.

Role of MicroRNA-502-3p in Human Diseases.

Devara D, Choudhary Y, Kumar S Pharmaceuticals (Basel). 2023; 16(4).

PMID: 37111289 PMC: 10144852. DOI: 10.3390/ph16040532.

Small noncoding RNAs play superior roles in maintaining hematopoietic stem cell homeostasis.

Wang H, Qian W, Han Y, Qian P Blood Sci. 2022; 4(3):125-132.

PMID: 36518603 PMC: 9742093. DOI: 10.1097/BS9.0000000000000123.

Role of MicroRNA-7 (MiR-7) in Cancer Physiopathology.

Morales-Martinez M, Vega M Int J Mol Sci. 2022; 23(16).

PMID: 36012357 PMC: 9408913. DOI: 10.3390/ijms23169091.

References

Neelapu S, Gause B, Harvey L, Lee S, Frye A, Horton J . A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma. Blood. 2007; 109(12):5160-3. PMC: 1941785. DOI: 10.1182/blood-2006-12-063594. View

Dave S, Wright G, Tan B, Rosenwald A, Gascoyne R, Chan W . Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004; 351(21):2159-69. DOI: 10.1056/NEJMoa041869. View

Zhou Y, Chen L, Barlogie B, Stephens O, Wu X, Williams D . High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proc Natl Acad Sci U S A. 2010; 107(17):7904-9. PMC: 2867889. DOI: 10.1073/pnas.0908441107. View

Ota A, Tagawa H, Karnan S, Tsuzuki S, Karpas A, Kira S . Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res. 2004; 64(9):3087-95. DOI: 10.1158/0008-5472.can-03-3773. View

Pangault C, Ame-Thomas P, Ruminy P, Rossille D, Caron G, Baia M . Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent T(FH)-B cell axis. Leukemia. 2010; 24(12):2080-9. PMC: 3317889. DOI: 10.1038/leu.2010.223. View

Zhou B, Elledge S . The DNA damage response: putting checkpoints in perspective. Nature. 2000; 408(6811):433-9. DOI: 10.1038/35044005. View

Di Leva G, Croce C . Roles of small RNAs in tumor formation. Trends Mol Med. 2010; 16(6):257-67. PMC: 2885513. DOI: 10.1016/j.molmed.2010.04.001. View

Roehle A, Hoefig K, Repsilber D, Thorns C, Ziepert M, Wesche K . MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. Br J Haematol. 2008; 142(5):732-44. DOI: 10.1111/j.1365-2141.2008.07237.x. View

de Jong D . Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. J Clin Oncol. 2005; 23(26):6358-63. DOI: 10.1200/JCO.2005.26.856. View

10.

Husson H, Carideo E, Neuberg D, Schultze J, Munoz O, Marks P . Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays. Blood. 2002; 99(1):282-9. DOI: 10.1182/blood.v99.1.282. View

11.

Chang H, Blondal J, Benchimol S, Minden M, Messner H . p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin's lymphoma cell lines. Leuk Lymphoma. 1995; 19(1-2):165-71. DOI: 10.3109/10428199509059672. View

12.

Tagawa H, Seto M . A microRNA cluster as a target of genomic amplification in malignant lymphoma. Leukemia. 2005; 19(11):2013-6. DOI: 10.1038/sj.leu.2403942. View

13.

Andreasson U, Eden P, Peterson C, Hogerkorp C, Jerkeman M, Andersen N . Identification of uniquely expressed transcription factors in highly purified B-cell lymphoma samples. Am J Hematol. 2010; 85(6):418-25. DOI: 10.1002/ajh.21701. View

14.

Mendoza M, Er E, Blenis J . The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011; 36(6):320-8. PMC: 3112285. DOI: 10.1016/j.tibs.2011.03.006. View

15.

Schuler F, Hirt C, Dolken G . Chromosomal translocation t(14;18) in healthy individuals. Semin Cancer Biol. 2003; 13(3):203-9. DOI: 10.1016/s1044-579x(03)00016-6. View

16.

Lawrie C, Chi J, Taylor S, Tramonti D, Ballabio E, Palazzo S . Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. J Cell Mol Med. 2009; 13(7):1248-60. PMC: 4496139. DOI: 10.1111/j.1582-4934.2008.00628.x. View

17.

Mandelbaum J, Bhagat G, Tang H, Mo T, Brahmachary M, Shen Q . BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell. 2010; 18(6):568-79. PMC: 3030476. DOI: 10.1016/j.ccr.2010.10.030. View

18.

Iorio M, Ferracin M, Liu C, Veronese A, Spizzo R, Sabbioni S . MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65(16):7065-70. DOI: 10.1158/0008-5472.CAN-05-1783. View

19.

Mourelatos Z, Dostie J, Paushkin S, Sharma A, Charroux B, Abel L . miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs. Genes Dev. 2002; 16(6):720-8. PMC: 155365. DOI: 10.1101/gad.974702. View

20.

Cattoretti G, Lin K, Calame K . Commitment of B lymphocytes to a plasma cell fate is associated with Blimp-1 expression in vivo. J Immunol. 2000; 165(10):5462-71. DOI: 10.4049/jimmunol.165.10.5462. View